Triaziquone

Triaziquone

SCHEMBL33439

CCN.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
STAT3 P40763 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DNMT1 P26358 1/20 0.41
NSD2 O96028 3/20 0.34
APAF1 O14727 2/20 0.34
TDP2 O95551 2/20 0.34
HKDC1 Q2TB90 2/20 0.34
TTR P02766 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GALK1 P51570 1/20 0.33
BLM P54132 1/20 0.33
ATM Q13315 1/20 0.33
NOD2 Q9HC29 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL21358774 0.91 MAPT (0.43) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL610295 0.91 DNMT1 (0.42) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL149876 0.90 MAPT (0.46) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL5800741 0.89 DNMT1 (0.41) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL11428634 0.89 DNMT1 (0.41) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL10379983 0.89 DNMT1 (0.41) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL2160619 0.89 DNMT1 (0.41) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL11350903 0.89 HTT (0.42) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL5606305 0.89 HTT (0.42) HTTMAPTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL2216690 0.88 MAPT (0.39) HTTMAPTTP53STAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310333-A1 MESOPOROUS SILICA NANOPARTICLE CONTROLLED RELEASE SYSTEM, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2023-10-05 US disclosed
EP-4209230-A1 MESOPOROUS SILICA NANOPARTICLE CONTROLLED RELEASE SYSTEM, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF East China University of Science and Technology (CN) 2023-07-12 EP disclosed
WO-2023030459-A1 QUINOLINONE AMIDE-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 中国科学院上海药物研究所 2023-03-09 WO disclosed
EP-1973587-B1 METHODS AND SYSTEMS FOR PREPARING ANTIMICROBIAL FILMS AND COATINGS ALLACCEM INC (US) 2019-02-06 EP disclosed
US-9994444-B2 Bridged polycyclic compound based compositions for the inhibition and amelioration of disease ALLACCEM, INC. (US) 2018-06-12 US disclosed
US-9957395-B2 Methods and systems for coating a medical device ALLACCEM, INC. (US) 2018-05-01 US disclosed
US-9212286-B2 Methods and systems for coating a surface ALLACCEM, INC. (US) 2015-12-15 US disclosed
EP-2125026-B1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE ALLACCEM INC (US) 2014-09-24 EP disclosed
US-20130150809-A1 METHODS AND SYSTEMS FOR COATING A MEDICAL DEVICE ALLACCEM, INC. 2013-06-13 US disclosed
US-20130040924-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE ALLACCEM, INC. (US) 2013-02-14 US disclosed
US-20090069435-A1 Bridged polycyclic compound based compositions for topical applications for pets ALLACCEM, INC. 2009-03-12 US disclosed
US-20090054528-A1 Bridged polycyclic compound based compositions for coating oral surfaces in pets ALLACCEM, INC. 2009-02-26 US disclosed
US-20080275141-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE ALLACCEM, INC. 2008-11-06 US disclosed
EP-1973587-A2 METHODS AND SYSTEMS FOR PREPARING ANTIMICROBIAL FILMS AND COATINGS Allaccem, Inc. (US) 2008-10-01 EP disclosed
WO-2008103847-A2 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE ALLACCEM, INCORPORATED (US) 2008-08-28 WO disclosed
US-20080207581-A1 Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning ALLACCEM, INC. 2008-08-28 US disclosed
US-20080020127-A1 Methods and systems for coating a medical device ALLACCEM, INC. 2008-01-24 US disclosed
US-20080021212-A1 Methods and systems for preparing an antimicrobial composition ALLACCEM, INC. 2008-01-24 US disclosed
US-20070202342-A1 Applying to an oral surface (teeth or gums)one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning; dentistry; bonding agents, resin cements, sealants ALLACCEM, INC. 2007-08-30 US disclosed
WO-2007070801-A2 METHODS AND SYSTEMS FOR PREPARING ANTIMICROBIAL FILMS AND COATINGS ALLACCEM, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069435-A1 Bridged polycyclic compound based compositions for topical applications for pets OTC, SLC16A8, SLC16A7 HTT 3141/4885MAPT 1950/4885TP53 804/4885
US-20090054528-A1 Bridged polycyclic compound based compositions for coating oral surfaces in pets PAICS, SLC16A8, CAD HTT 3455/4885MAPT 2868/4885TP53 1199/4885
US-20080021212-A1 Methods and systems for preparing an antimicrobial composition DNMT1, TET2, POLR1C HTT 2528/4885MAPT 4603/4885TP53 1873/4885
US-20130040924-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE PKD1, VHL, PKD2 HTT 127/4885MAPT 1400/4885TP53 983/4885
US-20080207581-A1 Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning DNMT1, TET2, CD14 HTT 3271/4885MAPT 4796/4885TP53 2722/4885
US-20230310333-A1 MESOPOROUS SILICA NANOPARTICLE CONTROLLED RELEASE SYSTEM, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SUCNR1, GOT1, BPGM HTT 2709/4885MAPT 3325/4885TP53 2711/4885
US-20080275141-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE PKD1, VHL, PKD2 HTT 127/4885MAPT 1400/4885TP53 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.